Daptomycin-induced rhabdomyolysis complicated with acute gouty arthritis
Issued Date
2023-05-01
Resource Type
ISSN
00029629
eISSN
15382990
Scopus ID
2-s2.0-85150022249
Pubmed ID
36693494
Journal Title
American Journal of the Medical Sciences
Volume
365
Issue
5
Start Page
450
End Page
456
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of the Medical Sciences Vol.365 No.5 (2023) , 450-456
Suggested Citation
Abdelnabi M., Leelaviwat N., Liao E.D., Motamedi S., Pangkanon W., Nugent K. Daptomycin-induced rhabdomyolysis complicated with acute gouty arthritis. American Journal of the Medical Sciences Vol.365 No.5 (2023) , 450-456. 456. doi:10.1016/j.amjms.2023.01.005 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82658
Title
Daptomycin-induced rhabdomyolysis complicated with acute gouty arthritis
Other Contributor(s)
Abstract
Rhabdomyolysis is a well-documented side effect of daptomycin and is associated with hyperuricemia. However, the occurrence of acute gouty arthritis secondary to rhabdomyolysis-induced hyperuricemia has not been reported. We report a case of a patient who presented with daptomycin-induced rhabdomyolysis prior to the usual 7-10-day administration period. This case was complicated with acute gouty arthritis after 7 days from the onset of rhabdomyolysis symptoms. Treatment consisted of fluid management with the addition of prednisone for gouty arthritis treatment given his poor kidney function. This report indicates the importance of early monitoring of creatine kinase levels in patients on daptomycin to prevent complications from rhabdomyolysis.